Summary
An overview of antihypertensive trials shows that, when absolute rather than relative measures of benefit are considered, a large benefit is derived from treating severe hypertension, whereas in mild hypertension the rate of prevented morbid events is relatively small. However, a greater benefit is observed when a mildly elevated diastolic blood pressure is associated with other risk factors. Thus, antihypertensive therapy in the 1990s needs to be regarded as a component, albeit an important one, in a multiple-strategy approach to prevention and reversal of cardiovascular diseases.
At a time when many different classes of antihypertensive agents are available, it is reasonable to ask whether some classes are more suitable than others for the treatment of patients with hypertension and concomitant risk factors such as dyslipidaemias and reduced glucose tolerance. It is well known that thiazide diuretics and β-blockers have potentially adverse effects on lipid and glucose metabolism, that calcium antagonists and ACE-inhibitors are lipid neutral and that α-blockers have potentially favourable effects. Although the real impact of some of these changes is unproven, it is possible that one or more of the metabolic side effects of drugs such as diuretics and β-blockers may offset some of the benefits of reduced blood pressure. Extensive testing of antihypertensive drugs with a favourable profile can be foreseen in the 1990s.
Similar content being viewed by others
References
Amery A, Birkenhäger W, Brixko P, Bulpitt C, Clement D, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1: 1349–1354, 1985
Amery A, Berthaux P, Bulpitt C, Deruyttere M, de Schaepdryver A, et al. Glucose intolerance during diuretic therapy. Lancet 1: 681–683, 1978
Amery A, Fagard R, Staessen J. Recent data on changes in lipid metabolism by hypotensive drugs. Current Opinion in Cardiology 2: 769–774, 1987
Australian Therapeutical Trial in Mild Hypertension: Management Committee Report. Lancet 1: 1261–1267, 1980
Australian Therapeutic Trial in Mild Hypertension: Management Committee Report. Untreated mild hypertension. Lancet 1: 185–191, 1982
Collins R, Peto R, MacMahon S, Herbert P, Fiebach NH, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335: 827–838, 1990
Hageland A. Treatment of mild hypertension: a five-year controlled drug trial: the Oslo Study. American Journal of Medicine 69: 725–732, 1980
Hamilton M, Thompson EW, Wisniewski TKM. The role of blood pressure control in preventing complications of hypertension. Lancet 1: 235–238, 1964
Hypertension Detection and Follow-up Program Cooperative Group. Reduction in mortality in persons with high blood pressure, including mild hypertension. Journal of the American Medical Association 242: 2562–2571, 1979
Medical Research Council Working Party. Mild to moderate hypertension: adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet 2: 539–543, 1981
Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal 291: 97–104, 1985
Medical Research Council Working Party. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. British Medical Journal 296: 1565–1570, 1988
Modam M, Halkin H, Almag S, Lusky A, Eshkol A, et al. Hyperinsulinemia, a link between hypertension obesity and glucose intolerance. Journal of Clinical Investigation 75: 809–817, 1985
Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. New England Journal of Medicine 321: 868–873, 1989b
Pollare T, Lithell H, Mörlin C, Präntare H, Hvarfner A, et al. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. Journal of Hypertension 7: 551–559, 1989c
Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 31: 415–420, 1988
Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double-blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. British Medical Journal 298: 1152–1157, 1989
Smith WM. Treatment of mild hypertension: results of a ten-year intervention trial. Public Health Service Hospitals Cooperative Study Group Circulation Research 40 (Suppl. 1): 98–105, 1977
Strasser T. Interference from drug trials: risk, probabilities, ethics, and decision taking. In Strasser T, Ganten D (Eds) Mild hypertension: from drug trials to practice, pp. 77–83, Raven Press, New York, 1987
Subcommittee Guidelines of the WHO/ISH Mild Hypertension Liaison Committee. 1989 Guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. Journal of Hypertension 7: 689–693, 1989
Swislocki ALM, Hoffman BB, Reaven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. American Journal of Hypertension 2: 419–423, 1989
Veterans Administration Cooperative Study Group on Anti-hypertensive Agents: effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115 through 129mm Hg. Journal of the American Medical Association 202: 1028–1034, 1967
Veterans Administration Cooperative Study Group on Hypertension. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114mm Hg. Journal of the American Medical Association 213: 1143–1152, 1970
WHO Expert Committee. Arterial hypertension, WHO Technical Report Series 628, 1978
Zanchetti A. The risk of hypertension: successes and failures of antihypertensive treatment. Journal of Human Hypertension 3(Suppl. 2): 27–33, 1989
Zanchetti A. What blood pressure level should be treated? In Laragh JH, Brenner BM (Eds) Hypertension: pathophysiology, diagnosis and management, pp. 1967–1983, Raven Press, New York, 1990a
Zanchetti A. Stepwise treatment of hypertension. In Ganten D, Mulrow PJ (Eds) Handbook of Experimental Pharmacology, Vol. 93, pp. 741–763, Pharmacology of Antihypertensive Therapeutics, Springer Verlag, Berlin-Heidelberg, 1990b
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zanchetti, A. Overview and Perspectives of Antihypertensive Treatment. Drugs 40 (Suppl 4), 85–91 (1990). https://doi.org/10.2165/00003495-199000404-00027
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199000404-00027